This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Alzheimer's disease and dementia
  • /
  • Cannabinoids for the treatment of neuropsychiatric...
Journal

Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia.

Read time: 1 mins
Published:1st Mar 2018
Author: Sherman C, Ruthirakuhan M, Vieira D, Lanctôt KL, Herrmann N.
Availability: Pay for access, or by subscription
Ref.:Curr Opin Psychiatry. 2018;31(2):140-146.
DOI:10.1097/YCO.0000000000000399


Purpose of review:
Efficacious treatment for neuropsychiatric symptoms (NPS), pain and weight loss for dementia patients is desperately needed. This review presents an up-to-date look at the literature investigating the use of cannabinoid for these symptoms in dementia.

Recent findings: We searched electronically for publications regarding cannabinoid use in dementia, with a focus on Alzheimer's disease. Seven studies and one case report have been conducted to examine the use of cannabinoids for the treatment of NPS of dementia, and three of these trials reported on the effect of cannabinoids on weight. Five studies reported decreased agitation or improvements in sleep with cannabinoid use. One crossover trial found that cannabinoids positively impacted weight, whereas a chart review study found no impact on weight with cannabinoids, but an increase in food intake. There were no trials examining the use of cannabinoids for pain in dementia.

Summary: Findings from trials with small sample sizes and various clinical populations suggest that cannabinoid use may be well tolerated and effective for treatment of NPS such as agitation as well as weight and pain management in patients with dementia. Additional studies are necessary to further elucidate the relative risks and benefits of this treatment.

 

Read abstract on library site

Access full article